Bluefin Achieves Girocard Certification for the Newland Payment Technology N950 AIO smartPOS
18.2.2025 15:00:00 CET | Business Wire | Press release
Bluefin has achieved the German Banking Industry Committee’s (GBIC German: Deutsche Kreditwirtschaft) Girocard certification on the Newland NPT N950 AIO smartPOS terminal. This certification enables German merchants to adopt next-generation SmartPOS devices while simplifying Girocard payment acceptance through Bluefin’s TECS Engine, a global payments platform.
Bluefin’s TECS Engine provides omnichannel payment solutions to Acquirers, Payment Service Providers, POS system providers, Independent Software Vendors (ISVs) and other merchant aggregators around the globe offering a cloud-based Payments Platform-as-a-Service, including Bluefin’s payment and data security solutions, P2PE and universal tokenization.
As the leading debit card in Germany, Girocard conducted 7.5 billion transactions in 2023. With Girocard certification on the Newland N950 AIO smartPOS terminal, the German market will benefit from an open platform with access to new generations of SmartPOS devices and streamlined Girocard payment acceptance while benefitting from lower merchant service fees.
“Achieving Girocard certification for the Newland N950 AIO smartPOS is a key milestone for TECS and Bluefin, reinforcing our commitment to delivering secure, innovative, and globally adaptable payment solutions,” said Anton Scheiber, International Sales & Business Development Director, Bluefin. “This certification provides new opportunities for merchants in Germany, giving them access to innovative SmartPOS technology while ensuring seamless Girocard payment acceptance.”
The Newland N950 is an Android SmartPOS terminal designed for seamless and secure payments across industries like retail, hospitality, and dining. Featuring a sleek touchscreen display and support for multiple payment methods – including chip and PIN, contactless, NFC, and QR-code payments – the N950 enhances customer engagement while streamlining transactions.
“We are excited to partner with Bluefin to bring the Newland N950 to the German market with Girocard certification,” said Kazem Aminaee, International President at Newland Payment Technology. “As a next-generation SmartPOS solution, the N950 combines advanced payment technology with a flexible platform, empowering businesses to enhance their payment experience while supporting Germany’s leading domestic debit card.”
About Bluefin
Bluefin is the recognized integrated payments leader in encryption and tokenization technologies that protect payments and sensitive data. Our product suite includes solutions for contactless, face-to-face, call center, mobile, E-commerce and unattended payments and data in the healthcare, higher education, government and nonprofit industries. The company’s 300 global partners serve 35,000 connected enterprise and software clients operating in 60 countries. Bluefin is a Participating Organization (PO) of the PCI Security Standards Council (SSC) and is headquartered in Atlanta, with offices in Waterford, Ireland and Vienna, Austria. For more information, visit https://www.bluefin.com/.
About Newland NPT
Newland NPT (Newland Payment Technology) is a leading global provider of payment acceptance technology. With over 30 years’ experience supplying best-in-class solutions, and working with partners in over 120 countries, Newland has successfully deployed over 100 million payment devices worldwide. For more information, visit https://www.newlandnpt.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218500456/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom